Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Asthma ; : 1-8, 2024 Mar 12.
Artigo em Inglês | MEDLINE | ID: mdl-38470879

RESUMO

OBJECTIVE: To evaluate the economic value of mepolizumab as an add-on therapy to the standard of care (SoC) for patients with severe eosinophilic asthma in China. METHODS: A Markov model with three health conditions was constructed to calculate the incremental cost per quality-adjusted life year (QALY) in mepolizumab with SoC and SoC only groups from the perspective of the Chinese healthcare system throughout an entire lifespan. The model was populated with local costs, while efficacy parameters were obtained from the global Phase III MENSA trial and mortality was derived from two surveys. One-way and probabilistic sensitivity analyses were conducted. Additional scenario analysis was used to estimate the cost-effectiveness impact of changes in the price of mepolizumab. RESULTS: Over the lifetime treatment horizon, the incremental cost-effectiveness ratio (ICER) of mepolizumab plus SoC compared to SoC alone was $170 648.73 per QALY. Sensitivity analyses focused on these results. Scenario analysis showed that mepolizumab would require a price reduction of at least 82% to reach the current willingness-to-pay (WTP=$38 223.34/QALY) threshold. CONCLUSION: Mepolizumab is not a cost-effective healthcare resource in China at its current pricing.

2.
China Pharmacy ; (12): 1880-1886, 2020.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-823360

RESUMO

OBJECTIVE:To evaluate the economic value of dapagliflozin combined with metformin in the treatment of type 2 diabetes mellitus (T2DM). METHODS :Based on related literatures and phase 3 randomized controlled clinical trial (RCT)of metformin alone or combined with dapagliflozin for T2DM,Markov model was built to simulate the dynamic changes of 3 schemes such as 5 mg dapagliflozin combined with metformin ,10 mg dapagliflozin combined with metformin or metformin alone (the dose of metformin were all 1 500 mg)in the treatment of T 2DM patients without or with complications and death . Quality adjusted life years(QALYs)was used as a health output indicator and the threshold of willingness-to-pay was 3 times of GDP in 2019. Cohort simulation in Markov model was applied to obtain long-term effect and cost of 3 schemes in the treatment of T 2DM. The incremental cost-effectiveness ratio (ICER)was analyzed ;the sensitivity of cost ,utility and discount was analyzed to check the stability of the analysis result. RESULTS :According to the results of Markov model cohort simulation ,after 10 years of disease progression,compared with metformin alone ,ICER of 5 mg dapagliflozin combined with metformin was 41 259.17 yuan/QALYs, and that of 10 mg dapagliflozin combined with metformin was 92 824.85 yuan/QALYs. Compared with 5 mg dapagliflozin combined with metformin ,ICER of 10 mg dapagliflozin combined with metformin was 1 209 525.95 yuan/QALYs. Extension of termination time to 20 or 30 years had no effect on results. According to the sensitivity analysis ,the change of key parameters in the set range did not affect the model results ,indicating the result was stable. CONCLUSIONS :For T 2DM,5 mg dapagliflozin combined with metformin is more cost-effective .

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...